CD274 and cancer: We constructed a pan-cancer cohort with anti-PD-1/PDL1 immunotherapy consisting of 1,959 cases based on four cohorts (17, 22–24) (Table S11), and patients with mutation exhibited a significantly clinical response to immunotherapy and markedly prolonged survival in ccRCC (Figures 5A, B).